Inventiva (NASDAQ:IVA) Stock Price Up 10.8% – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price rose 10.8% during mid-day trading on Monday . The stock traded as high as $5.83 and last traded at $5.9480. Approximately 58,752 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 422,250 shares. The stock had previously closed at $5.37.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price for the company. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Leerink Partners assumed coverage on Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Barclays assumed coverage on Inventiva in a report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Trading Up 7.5%

The firm has a fifty day moving average price of $5.74 and a 200 day moving average price of $5.34.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million for the quarter. As a group, sell-side analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current year.

Hedge Funds Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in Inventiva in the 4th quarter worth approximately $60,000. ADAR1 Capital Management LLC acquired a new position in Inventiva in the 4th quarter worth approximately $12,601,000. XTX Topco Ltd acquired a new position in Inventiva in the 4th quarter worth approximately $84,000. Yu Fan acquired a new position in Inventiva in the 4th quarter worth approximately $6,975,000. Finally, Ikarian Capital LLC acquired a new position in Inventiva in the 4th quarter worth approximately $2,329,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.